Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Memory and cognition-focused biopharmaceutical firm Saegis Pharmaceuticals has initiated a phase II clinical study of its lead product candidate, SGS742, in adult ADHD patients.
Subscribe to our email newsletter
The phase II trial is a placebo-controlled, double-blind crossover study, where patients will be randomized to receive either placebo or active drug, and then crossed over to the alternate agent. The trial will measure improvement in standard ADHD scales, and is expected to be completed in Q3 2005.
“In preclinical and clinical studies, SGS742 has consistently shown positive benefits on the ability to improve attention, learning and memory,” said Dr Rodney Pearlman, president and CEO of Saegis. “We are excited to be conducting an efficacy study among the adult ADHD population where safe, non-stimulatory medicines are needed.”
SGS742 is also currently being evaluated in randomized phase II clinical studies for the treatment of mild to moderate Alzheimer’s disease. Saegis has reported positive findings from a previously completed phase II clinical trial of SGS742 in mild cognitive impairment. Results from this trial demonstrated that patients treated with SGS742 exhibited improvements in multiple cognitive domains, including psychomotor skills, attention and memory.